Molecular profiles of genomically high risk ER+ HER2- breast cancer tumors classified as functionally basal or luminal B by the 80-gene signature.

Authors

Joyce O'Shaughnessy

Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX

Joyce O'Shaughnessy , Virginia G. Kaklamani , Yuan Yuan , Julie Barone , Sami Diab , Jennifer A. Crozier , Pat W. Whitworth , Karen L. Tedesco , Robert Maganini , Rakhshanda Layeequr Rahman , Carlos A. Encarnacion , Josien Haan , Amy Michelle Truitt , Andrea Menicucci , William Audeh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Biologic Correlates

Clinical Trial Registration Number

NCT03053193

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 563)

DOI

10.1200/JCO.2021.39.15_suppl.563

Abstract #

563

Poster Bd #

Online Only

Abstract Disclosures

FEATURED

Molecular profiles of genomically high risk ER+ HER2- breast cancer tumors classified as functionally basal or luminal B by the 80-gene signature.

Authors

Joyce O'Shaughnessy

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Predicting epirubicin response in Danish patients with breast cancer.

Poster

Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician’s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC).

Poster

evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).

Poster

Interim analyses (IA) of the giredestrant (G), G + abemaciclib (A), and G + ribociclib (R) arms in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2– LA/mBC).